New eye drops aim to soothe Sjogren's dry eye sufferers
NCT ID NCT05136170
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tested cenegermin (Oxervate) eye drops against a placebo in 85 adults with severe dry eye caused by Sjogren's syndrome, who were already using cyclosporine drops. The goal was to see if cenegermin could increase tear production and reduce eye discomfort over 4 weeks of treatment, with follow-up for several months. The trial is now complete, and results will show whether this nerve growth factor treatment offers extra relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenegermin (recombinant human Nerve Growth Factor) eye drops
What this could lead to
If it works, this could provide a new treatment option for people with severe dry eye from Sjogren's disease, improving tear production and comfort.
What could go wrong
This is a relatively small Phase 3 trial (85 people) and results may not apply to everyone. The treatment is added on top of existing therapy, so benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Gaspare Rodolico - Ospedale San Marco
Catania, 95123, Italy
-
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica
Roma, 00161, Italy
-
Houston Eye Associates HEA - Gramercy Location
Houston, Tennessee, 77025, United States
-
Lugene Eye Institute - Glendale Office
Glendale, California, 91204, United States
-
OCLI (Ophthalmic Consultants of Long Island)
Garden City, New York, 11530, United States
-
Scheie Eye Institute
Philadelphia, Pennsylvania, 19104, United States
-
The Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Toyos Clinic - Nashville
Nashville, Tennessee, 37215, United States
-
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica
Milan, 20123, Italy